PMID- 31832711
OWN - NLM
STAT- MEDLINE
DCOM- 20200603
LR  - 20211204
IS  - 1432-0614 (Electronic)
IS  - 0175-7598 (Linking)
VI  - 104
IP  - 2
DP  - 2020 Jan
TI  - Targeting PI3K/AKT/mTOR-mediated autophagy for tumor therapy.
PG  - 575-587
LID - 10.1007/s00253-019-10257-8 [doi]
AB  - Autophagy is a highly conserved catabolic process and participates in a variety 
      of cellular biological activities. The phosphoinositide 3-kinase (PI3K)/protein 
      kinase B (AKT)/mammalian target of rapamycin (mTOR) pathway, as a critical 
      regulator of autophagy, is involved in the initiation and promotion of a series 
      of pathological disorders including various tumors. Autophagy also participates 
      in regulating the balance between the tumor and the tumor microenvironment. 
      Natural products have been considered a treasure of new drug discoveries and are 
      of great value to medicine. Mounting evidence has suggested that numerous natural 
      products are targeting PI3K/AKT/mTOR-mediated autophagy, thereby suppressing 
      tumor growth. Furthermore, autophagy plays a "double-edged sword" role in 
      different tumors. Targeting PI3K/AKT/mTOR-mediated autophagy is an important 
      therapeutic strategy for a variety of tumors, and plays important roles in 
      enhancing the chemosensitivity of tumor cells and avoiding drug resistance. 
      Therefore, we summarized the roles of PI3K/AKT/mTOR-mediated autophagy in 
      tumorigenesis, progression, and drug resistance of tumors, which may be utilized 
      to design preferably therapeutic strategies for various tumors.
FAU - Xu, Zhenru
AU  - Xu Z
AD  - Department of Rheumatology, The First Affiliated Hospital of University of South 
      China, Hengyang, Hunan, China.
FAU - Han, Xu
AU  - Han X
AD  - Molecular Biology Research Center & Center for Medical Genetics, School of Life 
      Sciences, Central South University, Changsha, Hunan, China.
FAU - Ou, Daming
AU  - Ou D
AD  - Department of Rheumatology, The First Affiliated Hospital of University of South 
      China, Hengyang, Hunan, China.
FAU - Liu, Ting
AU  - Liu T
AD  - Department of Rheumatology, The First Affiliated Hospital of University of South 
      China, Hengyang, Hunan, China.
FAU - Li, Zunxiong
AU  - Li Z
AD  - University of South China, Hengyang, Hunan, China.
FAU - Jiang, Guanmin
AU  - Jiang G
AD  - Department of Clinical Laboratory, The Fifth Affiliated Hospital of Sun Yat-sen 
      University, Zhuhai, Guangdong, China.
FAU - Liu, Jing
AU  - Liu J
AD  - Molecular Biology Research Center & Center for Medical Genetics, School of Life 
      Sciences, Central South University, Changsha, Hunan, China. 
      jingliucsu@hotmail.com.
FAU - Zhang, Ji
AU  - Zhang J
AD  - Department of Rheumatology, The First Affiliated Hospital of University of South 
      China, Hengyang, Hunan, China. zhang_ji001@hotmail.com.
LA  - eng
GR  - 81870105/National Natural Science Foundation of China/
GR  - 81770107/National Natural Science Foundation of China/
GR  - 2018YFA0107800/National Key Research and Development Program of China/
PT  - Journal Article
PT  - Review
DEP - 20191212
PL  - Germany
TA  - Appl Microbiol Biotechnol
JT  - Applied microbiology and biotechnology
JID - 8406612
RN  - EC 2.7.11.1 (Proto-Oncogene Proteins c-akt)
RN  - EC 2.7.11.1 (TOR Serine-Threonine Kinases)
SB  - IM
MH  - Animals
MH  - *Autophagy
MH  - *Carcinogenesis
MH  - Humans
MH  - Neoplasms/*physiopathology/therapy
MH  - Phosphatidylinositol 3-Kinases/*metabolism
MH  - Proto-Oncogene Proteins c-akt/*metabolism
MH  - *Signal Transduction
MH  - TOR Serine-Threonine Kinases/*metabolism
OTO - NOTNLM
OT  - Autophagy
OT  - Drug resistance
OT  - PI3K/AKT/mTOR
OT  - Tumor
OT  - Tumor microenvironment
EDAT- 2019/12/14 06:00
MHDA- 2020/06/04 06:00
CRDT- 2019/12/14 06:00
PHST- 2019/08/02 00:00 [received]
PHST- 2019/11/12 00:00 [accepted]
PHST- 2019/11/05 00:00 [revised]
PHST- 2019/12/14 06:00 [pubmed]
PHST- 2020/06/04 06:00 [medline]
PHST- 2019/12/14 06:00 [entrez]
AID - 10.1007/s00253-019-10257-8 [pii]
AID - 10.1007/s00253-019-10257-8 [doi]
PST - ppublish
SO  - Appl Microbiol Biotechnol. 2020 Jan;104(2):575-587. doi: 
      10.1007/s00253-019-10257-8. Epub 2019 Dec 12.